Shares of Cipher Pharmaceuticals Inc (TSE:CPH) (NASDAQ:CPHR) fell 0.2% on Monday . The company traded as low as C$5.10 and last traded at C$5.11. 9,600 shares were traded during trading, a decline of 38% from the average session volume of 15,602 shares. The stock had previously closed at C$5.10.

A number of brokerages recently weighed in on CPH. TD Securities upped their price target on shares of Cipher Pharmaceuticals from C$5.50 to C$6.50 in a research report on Monday, August 14th. Bloom Burton cut shares of Cipher Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, August 14th.

In other Cipher Pharmaceuticals news, Director Harold Morton Wolkin purchased 35,000 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The stock was purchased at an average cost of C$4.69 per share, with a total value of C$164,150.00.

COPYRIGHT VIOLATION WARNING: This news story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/12/11/cipher-pharmaceuticals-cph-trading-down-0-2.html.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc, together with its subsidiaries, operates as a specialty pharmaceutical dermatology company in South America, Canada, and the United States. It offers CIP-ISOTRETINOIN, a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; CIP-FENOFIBRATE, a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and CIP-TRAMADOL ER, a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain.

Receive News & Ratings for Cipher Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.